Jenika Miles
Psychiatric/Mental Health · Wilmington, DENPI 1255503892
Payments from drug & device makers
What this record shows
24 manufacturers reported payments, led by AbbVie at 56.6% of the total. Reporting peaked in 2021 at $2,363 and has fallen 58.8% since, to $974 in 2025. Among psychiatric/mental health clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 281 payments — averaging $28.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Otsuka America Pharmaceutical, Inc.$564
- Alkermes, Inc.$340
- Neurocrine Biosciences, Inc.$299
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$291
- Johnson & Johnson$243
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$3,85047%
- Food & beverage$4,27753%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 64 | $4,596 |
| Otsuka America Pharmaceutical, Inc. | 26 | $564 |
| Alkermes, Inc. | 21 | $340 |
| Neurocrine Biosciences, Inc. | 18 | $299 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $291 |
| Johnson & Johnson | 15 | $243 |
| Teva Pharmaceuticals USA, Inc. | 15 | $240 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $225 |
| Vanda Pharmaceuticals Inc. | 11 | $180 |
| Lundbeck LLC | 11 | $167 |
| Axsome Therapeutics, Inc. | 9 | $162 |
| Sunovion Pharmaceuticals Inc. | 13 | $125 |
| Idorsia Pharmaceuticals US Inc | 8 | $122 |
| Corium, LLC | 7 | $120 |
| Ironshore Pharmaceuticals Inc. | 7 | $99 |
| Bausch Health US, LLC | 6 | $86 |
| Supernus Pharmaceuticals, Inc. | 4 | $64 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Neos Therapeutics, LP | 3 | $42 |
| Almatica Pharma LLC | 2 | $30 |
| Eisai Inc. | 2 | $25 |
| Novo Nordisk | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,127 in reported general payments places this provider in the 95th percentile of 177 psychiatric/mental health providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 18 | $165,149 |
| IngrezzaValbenazine Tosylate | 17 | $133,986 |
| RexultiBrexpiprazole | 61 | $87,812 |
| Invega SustennaPaliperidone Palmitate | 22 | $48,443 |
| VraylarCariprazine Hcl | 26 | $45,400 |
| Divalproex Sodium | 183 | $19,890 |
| Divalproex Sodium ErDivalproex Sodium | 208 | $16,998 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $14,591 |
| Chlorpromazine Hcl | 62 | $13,942 |
| Aripiprazole | 293 | $12,995 |
| Risperidone | 323 | $7,248 |
| Quetiapine Fumarate | 245 | $6,709 |
| BelsomraSuvorexant | 15 | $6,584 |
| Paliperidone ErPaliperidone | 28 | $5,982 |
| Lorazepam | 364 | $5,215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $243 | $213,59240 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $299 | $133,98617 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $564 | $87,81261 claims |
| AbbVieVraylar | $4,596 | $45,40026 claims |
| Almatica Pharma LLCSertraline Hcl | $30 | $2,375170 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 psychiatric/mental health providers in Delaware.
Other psychiatric/mental health in Wilmington
- Ronald TyreeWilmington$59K
- Stephanie McKayWilmington$6K
- Jacqueline ArmstrongWilmington$6K
- Elizabeth SewardWilmington$6K
- Jennifer RogersWilmington$5K
- Olamide VincentWilmington$5K
- Edwin SokalskiWilmington$5K
- Lisa ToyWilmington$5K
- Earl RobinsonWilmington$4K
- Katrese ThomasWilmington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.